Lead time of carcinoembryonic antigen elevation in the postoperative follow-up of colorectal cancer did not affect the survival rate after recurrence
- PMID: 20162425
- DOI: 10.1007/s00384-010-0889-6
Lead time of carcinoembryonic antigen elevation in the postoperative follow-up of colorectal cancer did not affect the survival rate after recurrence
Abstract
Background and aims: The role of carcinoembryonic antigen (CEA) in the early detection of recurrence during the postoperative follow-up of colorectal cancer remains unclear. We hypothesize that the tumor with longer lead time of CEA elevation to the definite recurrence may have a better prognosis because of its slower growth rate and closer observation.
Materials and methods: From 1995 to 2003, 4,841 consecutive patients who received curative resection of localized colorectal adenocarcinoma were enrolled from a prospective database. The patients with persisting CEA elevation after operation had been already excluded. Postoperative follow-up, including physical examination, imaging, and CEA test, were performed according to a surveillance program. A CEA >/=5 ng/mL was defined as elevated. The definition of the CEA lead time was the period between CEA elevation and detection of recurrence. All statistical analyses were performed by SPSS package for Windows (Microsoft, Redmond, WA, USA).
Results: The postoperative median follow-up time for the 4,841 patients was 68 months. A total of 999 patients (20.6%) had CEA elevation and recurrence. Among these patients, recurrence was confirmed in 727 patients (72.8%)before, at the same time, or within 3 months of CEA elevation and thus had a short lead time of CEA elevation (SLT group). In 272 patients (27.2%), recurrence was confirmed after more than 3 months of CEA elevation and thus had a longer lead time of CEA elevation (LLT group). The recurrence pattern showed similarities in these two groups. A total of 193 patients (193/999, 19.3%) received a second radical operation, and 806 patients (80.7%) were inoperable. The re-resection rate between the SLT group (146 patients, 20.1%) and the LLT group (47 patients, 17.3%) was not significantly different. The overall survival rate after recurrence showed no difference between these two groups (P = 0.123).
Conclusion: Most cases of recurrence were detected at nearly the same time when the CEA level was elevated. Therefore, a more sensitive test is needed for early detection. The relationship between the lead time of CEA and the clinical outcome was not statistically significant. A more aggressive approach to the patient who has CEA elevation and is highly suspect of recurrence may be needed.
Similar articles
-
Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level.Ann Surg Oncol. 2009 Nov;16(11):3087-93. doi: 10.1245/s10434-009-0625-z. Epub 2009 Jul 23. Ann Surg Oncol. 2009. PMID: 19629600
-
The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer.Langenbecks Arch Surg. 2000 Jul;385(4):271-5. doi: 10.1007/s004230000136. Langenbecks Arch Surg. 2000. PMID: 10958511
-
Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.J Surg Res. 2016 Oct;205(2):384-392. doi: 10.1016/j.jss.2016.06.078. Epub 2016 Jul 4. J Surg Res. 2016. PMID: 27664887
-
Value of carcinoembryonic antigen in the management of colorectal cancer.Dis Colon Rectum. 1994 Mar;37(3):272-7. doi: 10.1007/BF02048166. Dis Colon Rectum. 1994. PMID: 8137675 Review.
-
Carcinoembryonic antigen screening: pros and cons.Semin Oncol. 1999 Oct;26(5):556-60. Semin Oncol. 1999. PMID: 10528904 Review.
Cited by
-
Blood CEA levels for detecting recurrent colorectal cancer.Cochrane Database Syst Rev. 2015 Dec 10;2015(12):CD011134. doi: 10.1002/14651858.CD011134.pub2. Cochrane Database Syst Rev. 2015. PMID: 26661580 Free PMC article.
-
The prognostic significance and treatment modality for elevated pre- and postoperative serum CEA in colorectal cancer patients.Ann Surg Treat Res. 2016 Oct;91(4):165-171. doi: 10.4174/astr.2016.91.4.165. Epub 2016 Sep 30. Ann Surg Treat Res. 2016. PMID: 27757393 Free PMC article.
-
Clinical Significance of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/computed Tomography in the Follow-up of Colorectal Cancer: Searching off Approaches Increasing Specificity for Detection of Recurrence.Radiol Oncol. 2017 Nov 1;51(4):378-385. doi: 10.1515/raon-2017-0045. eCollection 2017 Dec. Radiol Oncol. 2017. PMID: 29333115 Free PMC article.
-
Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer.Cancers (Basel). 2021 Aug 2;13(15):3892. doi: 10.3390/cancers13153892. Cancers (Basel). 2021. PMID: 34359796 Free PMC article.
-
Elevated Serum Carcinoembryonic Antigen Is Associated with a Worse Survival Outcome of Patients After Liver Resection for Hepatocellular Carcinoma: a Propensity Score Matching Analysis.J Gastrointest Surg. 2016 Dec;20(12):2063-2073. doi: 10.1007/s11605-016-3295-8. Epub 2016 Oct 11. J Gastrointest Surg. 2016. PMID: 27730399
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical